Fresenius acquires assets from Hema Metrics

Fresenius Medical Care has acquired all assets of Hema Metrics LLC related to its Crit-Line system for an undisclosed amount. The deal includes all assets related to blood monitoring systems and the Crit-Line sales force, Mass Device reports. The Crit-Line system and its associated products are FDA 510(k) cleared and carry the CE mark.

According to its website, Salt Lake City-based Hema Metrics serves thousands of patients worldwide and provides products for more than 1 million treatments each year. Its Crit-Line III is a fluid management and access monitoring tool incorporating the latest photo-optical technology to non-invasively measure absolute hematocrit, percent blood volume change, continuous oxygen saturation and access recirculation.

The buy comes less than a month after Fresenius moved to challenge NxStage Medical in the home dialysis market, as Mass Device points out. Fresenius says it intends to establish this newly acquired technology as the standard of care for fluid and anemia management in the North American market. It adds the Crit-Line system is an excellent fit with Fresenius Medical Care North America's 2008K, 2008K2, and 2008T hemodialysis machines.

- get the Fresenius Medical Care release
- check out the Mass Device report

Suggested Articles

The U.S. regulator has given the green light to moderate-risk medical devices despite them not always meeting the FDA’s own standards.

Machine learning drug development company insitro has bought up Haystack Sciences, adding DNA-encoded libraries to its R&D arsenal.

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.